Ogier N et al. – Daily consumption of this new dietary supplement (DS) decreased LDL–cholesterol and total cholesterol (TC) and is therefore an interesting, convenient aid in managing mild to moderate hypercholesterolemia.Methods
- In a double–blind, randomized, parallel controlled study, 39 subjects from 21 to 55 years with moderate hypercholesterolemia without drug treatment were assigned to 2 groups and then consumed either a DS containing RYR, SCdP and ALEs or a placebo over a 16–week period.
- Plasma concentrations of lipids [LDL–cholesterol, total cholesterol (TC), high–density–lipoprotein cholesterol (HDL–cholesterol), triacylglycerols (TG)] and plasma levels of vitamins C and E, total polyphenols and malondialdehyde were determined at baseline and after 4, 8, 12 and 16 weeks.
- LDL–cholesterol and TC were reduced by, respectively, 21.4 % (95 % CI, –13.3 to –24.9 %, p < 0.001) and 14.1 % (95 % CI, –10.1 to –18.0 %, p < 0.001) at week 16 in the DS group compared with baseline.
- Similar results were obtained at weeks 4, 8 and 12.
- TG decreased by 12.2 % after 16 weeks in the DS group (95 % CI: –24.4 to –0.1 %, p < 0.05).
- For the vitamin E/TC ratio, a difference was observed between groups at week 16 (p < 0.05).
- Other parameters were not modified.